866-997-4948(US-Canada Toll Free)

Tasmar Analysis and Estimates from 2004 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 35 Pages


GlobalDatas pharmaceuticals report, Tasmar Analysis and Estimates from 2004 to 2020 provides Tasmarsales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2004-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Tasmar including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Tasmar including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2004-2020 for Tasmar in the US and EU5
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Parkinsons Disease 5
2.2 Symptoms of Parkinsons Disease 5
2.3 Diagnosis of Parkinsons Disease 6
2.4 Parkinsons Disease Treatment Strategies 6
2.5 Parkinsons Disease Market 7
2.6 Epidemiology 7
2.7 Parkinsons Disease by Age and Gender 7
2.8 Etiology 8
2.9 GlobalData Report Guidance 8

3 Parkinsons Disease: Market Characterization 9
3.1 Parkinsons Disease Market 9
3.2 Parkinsons Disease Market Forecasts and CAGR 9
3.3 Factors Affecting Parkinsons Disease Market 10
3.3.1 High Prevalence: Parkinsons Disease is the Second Most Frequent Neurodegenerative Disorder 10
3.3.2 Increase in Old Age Population 10
3.3.3 Patent Expiry of Prominent Drugs 10

4 Stages of Parkinsons Disease and Comparison of Treatments 11
4.1 The Hoehn and Yahr Scale 11
4.2 Modified Hoehn and Yahr Scale 11
4.3 The UPDRS 12

5 Staging of Parkinsons Disease 15
5.1 Distribution of Parkinsons Disease Patients by Age Groups 15
5.2 Distribution of Patients by Stages 15

6 Tasmar 16
6.1 Introduction 16
6.2 Mechanism of Action 16
6.3 Clinical Studies 16
6.4 Approval History of Tasmar 18
6.5 Factors Affecting Sales of Tasmar 18
6.5.1 Risk of Potentially Fatal, Acute Fulminant Liver Failure with Tasmar 18
6.5.2 Suspension of Tasmar from the US and EU 18
6.5.3 Patent Expiry of Tasmar 19
6.5.4 Tasmar Not Approved in Japan 19
6.6 Drug Evaluation 19
6.6.1 Drug Risk Benefit Score 19
6.6.2 Intensity of Competition 20
6.7 Sales Estimates 21
6.7.1 Target Patient Pool for Tasmar 21
6.7.2 Dosing 21
6.7.3 Market Penetration 22
6.7.4 Annual Cost of Therapy 22
6.7.5 Sales Estimates of Tasmar 23

7 Parkinson Disease Market: Appendix 31
7.1 Market Definitions 31
7.2 List of Abberiviations 31
7.3 Research Methodology 31
7.3.1 Coverage 31
7.3.2 Secondary Research 31
7.3.3 Forecasting 32
7.3.4 Number of Patients Approved to take the Drug 32
7.3.5 Net Penetration of Drug 32
7.3.6 Net Annual Dosing 33
7.3.7 Annual Cost of Therapy 33
7.3.8 Primary Research 33
7.3.9 Expert Panels 34
7.4 Drug Sales Estimates Model 34
7.5 Contact Us 34
7.6 Disclaimer 34
7.7 Sources 35

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 5
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 11
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 11
Table 4: Four Items, Part 1 of UPDRS 12
Table 5: Thirteen Items, Part 2 of UPDRS 12
Table 6: Fourteen Items, Part 3 of UPDRS 13
Table 7: Fourteen Items, Part 3 of UPDRS 13
Table 8: Distribution of Parkinsons Patients According to Hoehn and Yahr Classification 15
Table 9: Results of Phase III US/Canada Fluctuation Study 17
Table 10: Results of Phase III European Fluctuation Study 17
Table 11: Results of Phase III US/Canadian Non-Fluctuation Study 18
Table 12: Approval History of Tasmar 18
Table 13: Drug Risk Benefit Score 19
Table 14: Summary of Adverse Events 20
Table 15: Efficacy Comparison of Tasmar 21
Table 16: Dosing Details of Tasmar 21
Table 17: Annual Cost of Therapy of Tasmar, 2010 22
Table 18: Tasmar, Parkinsons Disease, Global, Sales Estimates ($m), 20042020 23
Table 19: Tasmar, Parkinsons Disease, The US, Sales Estimates ($m), 20042020 24
Table 20: Tasmar, Parkinsons Disease, The UK, Sales Estimates ($m), 20052020 25
Table 21: Tasmar, Parkinsons Disease, France, Sales Estimates ($m), 20052020 26
Table 22: Tasmar, Parkinsons Disease, Germany, Sales Estimates ($m), 20052020 27
Table 23: Tasmar, Parkinsons Disease, Italy, Sales Estimates ($m), 20052020 28
Table 24: Tasmar, Parkinsons Disease, Spain, Sales Estimates ($m), 20052020 29

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons Disease and Their Potential Sites of Action in the CNS 6
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 7
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 9
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 10
Figure 5: Points Distribution of UPDRS 14
Figure 6: Distribution of Parkinsons Disease Patients by Hoehn & Yahr Classification 15
Figure 7: Drug Model Diagram of Tasmar 21
Figure 8: Tasmar, Parkinsons Disease, Global, Sales Estimates ($m), 20042020 23
Figure 9: Tasmar, Parkinsons Disease, The US, Sales Estimates ($m), 20042020 24
Figure 10: Tasmar, Parkinsons Disease, The UK, Sales Estimates ($m), 20052020 25
Figure 11: Tasmar, Parkinsons Disease, France, Sales Estimates ($m), 20052020 26
Figure 12: Tasmar, Parkinsons Disease, Germany, Sales Estimates ($m), 20052020 27
Figure 13: Tasmar, Parkinsons Disease, Italy, Sales Estimates ($m), 20052020 28
Figure 14: Tasmar, Parkinsons Disease, Spain, Sales Estimates ($m), 20052020 29
Figure 15: Tasmar, Parkinsons Disease, Global, Sales Distribution by Country (%), 2011 30
Figure 16: Drug Model Diagram 33
Figure 17: Patients Approved for the Drug 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *